TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00814125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole (Arimidex)
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole (Arimidex)
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nolvadex placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex placebo
Study: NCT03088904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent vaccine
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study: NCT03205787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trifolium pratense
Description: Red Clover extract standardized to isoflavone content.
Study: NCT01215318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified vaginal tampon
Description: modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: modified vaginal tampon
Description: modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
Study: NCT02011022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3g MTX
Description: The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5g MTX
Description: The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
Study: NCT02700581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low PEEP conventional ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate PEEP conventional ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low PEEP protective ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate PEEP protective ventilation
Study: NCT02803515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral venous blood samples
Description: peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: peripheral venous blood samples
Description: peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
Study: NCT01271790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir (GS-9190)
Description: Tegobuvir (GS-9190) capsule, 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: GS-9451 tablet, 200 mg once daily (QD)
Study: NCT03921372

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: Squatting for 5 minutes
Study: NCT04139499

Intervention type: PROCEDURE
Intervention: Drug-induced sleep endoscopy (DISE)
Description: DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.

Intervention type: PROCEDURE
Intervention: Drug-induced sleep endoscopy (DISE)
Description: DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.

Intervention type: PROCEDURE
Intervention: Drug-induced sleep endoscopy (DISE)
Description: DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
Study: NCT04139499

Intervention type: PROCEDURE
Intervention: Drug-induced sleep endoscopy (DISE)
Description: DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.

Intervention type: PROCEDURE
Intervention: High-resolution manometry (HRM):
Description: After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.

Intervention type: PROCEDURE
Intervention: High-resolution manometry (HRM):
Description: After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.

Intervention type: PROCEDURE
Intervention: High-resolution manometry (HRM):
Description: After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.

Intervention type: PROCEDURE
Intervention: High-resolution manometry (HRM):
Description: After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
Study: NCT01271790

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus®
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study: NCT02252978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03418246

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GIC
Description: tooth colored filling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: White filling -Biodentine
Study: NCT01481246

Intervention type: BEHAVIORAL
Intervention: Categorization training
Description: Behavioral intervention consisting of cognitive training exercises to improve categorization performance

Intervention type: BEHAVIORAL
Intervention: Psychosocial and Psychoeducational Group training
Description: Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
Study: NCT01483846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
Study: NCT02400346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunct brexpiprazole
Description: Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg.
Study: NCT01312064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab and everolimus
Description: rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thymoglobulin and tacrolimus
Description: thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
Study: NCT03785730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-restorative cavity control - NRCC group
Description: The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with resin composite - RCR group
Description: In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
Study: NCT01181635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Standard psychotherapy for psychiatric disorders.
Study: NCT04522258

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber
Description: Fermentable cereal bran

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Refined cereal flour
Study: NCT01654484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Description: Ophthalmic Solution, QD, 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Description: Ophthalmic Solution, QD, 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Description: Ophthalmic Solution, QD, 28 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.0015% tafluprost
Description: Ophthalmic Solution, QD, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 and 0.0015% tafluprost
Description: Ophthalmic Solutions, QD, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 and 0.0015% tafluprost
Description: Ophthalmic Solutions, QD, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 and 0.0015% tafluprost
Description: Ophthalmic Solutions, QD, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic Solution, QD, 28 days
Study: NCT00608322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled nitric oxide, 40 parts per million, for six hours.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham inhaled nitric oxide
Description: Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
Study: NCT02153645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 240mg Amantadine HCl ER tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320mg Amantadine HCl ER tablets
Study: NCT01418573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palaeolithic meal 1
Description: Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palaeolithic meal 2
Description: Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference meal
Description: Based on WHO dietary guidelines for protein, fat and carbohydrate.
Study: NCT03413202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: butylphthalide(NBP)
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
Study: NCT02400346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
Study: NCT03213639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg Oral Tablet
Description: once daily oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: once daily oral tablets
Study: NCT01139762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 milligrams (mg) administered orally, once daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride
Description: 5mg administered orally, once daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 5mg administered orally, once daily for 26 weeks
Study: NCT01675596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Description: Operable subjects
Study: NCT00538239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Four 10 mg tablets taken by mouth for 5 days per week continuously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four 10 mg tablets taken by mouth for 5 days per week continuously
Study: NCT04128033

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Puncture of the placebo point
Description: Puncture of a placebo point outside the meridian, with no effect
Study: NCT01271790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: GS-9451 tablet, 200 mg QD
Study: NCT01590563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD
Description: Insertion of a spherical IUD, one year follow-up
Study: NCT01834183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01271790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir placebo
Description: placebo matching Tegobuvir (GS-9190) capsule BID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus®
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegobuvir placebo
Description: placebo matching Tegobuvir (GS-9190) capsule BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9451 placebo
Description: placebo matching GS-9451 tablet QD

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus®
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Study: NCT00949650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed IV given once every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 once daily until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV given once every 3 weeks for up to 6 cycles
Study: NCT03247998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Study: NCT04191096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT)
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
Study: NCT03864380

Intervention type: DIAGNOSTIC_TEST
Intervention: Color retinography
Description: Non mydriatic color retinography within 1 month before and within 1 hour after the marathon

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A
Description: Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement
Description: Blood pressure measurement within 1 month before and within 1 hour after the marathon
Study: NCT03835780

Intervention type: OTHER
Intervention: No intervention
Description: A observation of outcomes in usual practice

Intervention type: OTHER
Intervention: No intervention
Description: A observation of outcomes in usual practice

Intervention type: OTHER
Intervention: No intervention
Description: A observation of outcomes in usual practice

Intervention type: OTHER
Intervention: No intervention
Description: A observation of outcomes in usual practice
Study: NCT04191096

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
Study: NCT02965261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Fluoxetine Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warner Chilcott LLC Sarafem Tablets
Study: NCT00597454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose.
Study: NCT03503435

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group art therapy
Description: Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
Study: NCT03850158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.